search button
Open Access

Tumor necrosis factor‑related apoptosis‑inducing ligand additive with Iodine‑131 of inhibits non‑small cell lung cancer cells through promoting apoptosis

  • Authors:
    • Ning Yang
    • Shuzhan Yao
    • Dong Liu

  • View Affiliations

  • Published online on: May 4, 2018     https://doi.org/10.3892/ol.2018.8635
  • Pages: 276-284

  • Copyright: © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Non‑small‑cell lung cancer (NSCLC) accounts for ~80% of human lung cancer cases and is the most common cause of cancer‑associated mortality worldwide. Reports have indicated that tumor necrosis factor‑related apoptosis‑inducing ligand (TRAIL) and Iodine‑131 (I‑131) can induce tumor cell apoptosis. The purpose of the present study was to investigate the additive efficacy of TRAIL and I‑131 on NSCLC cells. The present study demonstrated that additive treatment of TRAIL and I‑131 (TRAIL‑I‑131) significantly inhibited the growth and aggressiveness of NSCLC cells compared with single TRAIL or I‑131 treatment. Results demonstrated that TRAIL‑I‑131 treatment induced apoptosis of NSCLC cells, with western blot analysis confirming that TRAIL‑I‑131 treatment increased proapoptotic Bad and Bax expression levels, while antiapoptotic Bcl‑2 and Bcl‑w protein levels were decreased in NSCLC cells. The present study demonstrated that TRAIL‑I‑131 treatment inhibited vascular endothelial growth factor (VEGF) and activator protein‑1 (AP‑1) in NSCLC cells. Potential mechanism analyses identified that TRAIL‑I‑131 treatment induced apoptosis of NSCLC cells through caspase‑9 activation. In vivo assays revealed that TRAIL‑I‑131 treatment significantly inhibited NSCLC tumor growth and increased apoptotic bodies in tumor tissues. Immunohistology demonstrated that caspase‑9 was upregulated and VEGF was downregulated in tumor tissues in TRAIL‑I‑131‑treated tumors. In conclusion, these results indicate that TRAIL combined with I‑131 promoted apoptosis of NSCLC through caspase‑9 activation, which may be a promising anticancer therapeutic schedule for the treatment of NSCLC.
View Figures
View References

Related Articles

Journal Cover

July-2018
Volume 16 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.9
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 6.3
  • CiteScore Rank: Q2: #119/366 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.725
  • SCImago Journal Rank (SJR): 0.639
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Yang N, Yao S and Liu D: Tumor necrosis factor‑related apoptosis‑inducing ligand additive with Iodine‑131 of inhibits non‑small cell lung cancer cells through promoting apoptosis. Oncol Lett 16: 276-284, 2018
APA
Yang, N., Yao, S., & Liu, D. (2018). Tumor necrosis factor‑related apoptosis‑inducing ligand additive with Iodine‑131 of inhibits non‑small cell lung cancer cells through promoting apoptosis. Oncology Letters, 16, 276-284. https://doi.org/10.3892/ol.2018.8635
MLA
Yang, N., Yao, S., Liu, D."Tumor necrosis factor‑related apoptosis‑inducing ligand additive with Iodine‑131 of inhibits non‑small cell lung cancer cells through promoting apoptosis". Oncology Letters 16.1 (2018): 276-284.
Chicago
Yang, N., Yao, S., Liu, D."Tumor necrosis factor‑related apoptosis‑inducing ligand additive with Iodine‑131 of inhibits non‑small cell lung cancer cells through promoting apoptosis". Oncology Letters 16, no. 1 (2018): 276-284. https://doi.org/10.3892/ol.2018.8635